Fidaxomicin Use in the Pediatric Population with Clostridioides difficile

Meredith B Oliver; Byron P Vaughn

doi:10.2147/CPAA.S273318

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile

Clin Pharmacol. 2022 Sep 23:14:91-98. doi: 10.2147/CPAA.S273318. eCollection 2022.

Authors

Meredith B Oliver¹, Byron P Vaughn²

Affiliations

¹ M Health Fairview, Masonic Children's Hospital, Minneapolis, MN, USA.
² Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USA.

Abstract

Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These features make it an appealing option for pediatric CDI to balance safety and efficacy. The purpose of this structured review was to outline the clinical evidence for safety and efficacy of fidaxomicin for pediatric CDI. A structured literature search was performed to identify relevant clinical data. Fidaxomicin is similarly effective to oral vancomycin with a lower rate of recurrent CDI. There were no serious safety signals reported with fidaxomicin. In conclusion, fidaxomicin is a safe and effective treatment option for pediatric CDI.

Keywords: Dificid; colitis; diarrhea; microbiota.

Publication types

Review